Geneva, Feb. 2 -- International Clinical Trials Registry received information related to the study (ACTRN12626000073303) titled 'SuPro - Sugammadex and its effect on Progestogens' on Jan. 20.
Study Type: Interventional
Study Design:
Purpose: Prevention
Allocation: Randomised controlled trial
Masking: Blinded (masking used)
Assignment: Parallel
Type of endpoint: Efficacy
Primary Sponsor: ANZCA Foundation
Condition:
Ovulation
Ovulation
Reproductive Health and Childbirth - Contraception
Intervention:
Participants assigned to this arm will receive a single dose of 2mg/kg of sugammadex intravenously for neuromuscular reversal at the end of the anaesthetic.
Recruitment Status: Not Recruiting
Phase: Phase 4
Date of First Enrollment:...